Lipid Parameters Including Lp(a) in Hemodialysis Patients

References

• Ma K W, Greene E L, Raij L. Cardiovascular risk factors; in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992; 19: 505–513
   PubMed Web of Science ®Google Scholar
• Rostand S G, Gretes J C, Kirk K A, Rutsky E A, Andreoli T E. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int 1979; 16: 600–611
   PubMed Web of Science ®Google Scholar
• Linder A L, Charra B, Sherrard D J, Scribner F J. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697–701
   PubMed Web of Science ®Google Scholar
• Grundy S M. Management of hyperlipidemia of kidney disease. Kidney Int 1990; 37: 847–853
   PubMed Web of Science ®Google Scholar
• Attman P O, Alaupovic P. Lipid abnormalities in chronic renal insufficiency. Kidney Int 1991; 31: S16–S23, suppl
   Google Scholar
• Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169–183
   PubMed Web of Science ®Google Scholar
• Bagdade J K, Porte D, Jr, Bierman E L. Hypertriglyceridemia—A metabolic consequence of chronic renal failure. N Engl J Med 1968; 279: 181–185
   PubMed Web of Science ®Google Scholar
• Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992; 41: 1653–1661
   PubMed Web of Science ®Google Scholar
• Attman P O, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. Increased concentrations of Apo B-containing triglyceride-rich lipoprotein particles in patients with chronic renal failure. Miner Electrolyte Metab 1992; 18: 199–202
   PubMedGoogle Scholar
• Attman P O, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. Relation to renal function and dialysis. Nephron 1991; 57: 401–410
   PubMed Web of Science ®Google Scholar
• Parra H J, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart J C. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987; 33: 721
   PubMed Web of Science ®Google Scholar
• Parsy D, Dracon M, Cachera C, Parra H-J, Vanhoutte G, Tacquet A, Fruchart J-C. Lipoprotein abnormalities in chronic hemodialysis patients. Nephrol Dial Transplant 1988; 3: 51–56
   PubMedGoogle Scholar
• Pelegri A, Romero R, Senti M, Nogués X, Pedro-Botet J, Rubiés Prat J. Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis. Nephrol Dial Transplant 1992; 7: 623–626
   PubMedGoogle Scholar
• Kandoussi A, Cachera C, Pagniez D, Dracon M, Fruchart J C, Tacquet A. Plasma level of lipoprotein (a) is high in predialysis or hemodialysis, but not in CAPD. Kidney Int 1992; 42: 424–425
   PubMed Web of Science ®Google Scholar
• Barbagallo C M, Averna M R, Scafidi V, Galione A, Notarbartolo A. Increased lipoprotein (a) levels in subjects with chronic renal failure on hemodialysis. Nephron 1992; 62: 471–472
   PubMedGoogle Scholar
• Cressman M D, Heyka R J, Paganini E P, O'Neil J, Skibinski C I, Hoff H F. Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475–482
   PubMed Web of Science ®Google Scholar
• Heimann P, Josephson M A, Fellner S K, Thistlethwaite J R, Jr., Stuart F P, Dasgupta A. Elevated lipoprotein (a) levels in renal transplantation and hemodialysis patients. Am J Nephrol 1991; 11: 470–474
   PubMedGoogle Scholar
• Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. High serum lipoprotein (a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 1992; 38(5)271–276
   PubMedGoogle Scholar
• Webb A T, Reaveley D A, O'Donnell M, O'Connor B, Seed M, Brown E A. Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8: 609–613
   PubMed Web of Science ®Google Scholar
• Barbagallo C M, Averna M R, Sparacino V, Galione A, Caputo F, Scafidi V, Amato S, Mancino C, Cefalù A B, Notarbartolo A. Lipoprotein (a) levels in end-stage renal failure and renal transplantation. Nephron 1993; 64: 560–564
   PubMedGoogle Scholar
• Goldwasser P, Michel M-A, Collier J, Mittman N, Fein P A, Gusik S-A, Avram M M. Prealbumin and lipoprotein (a) in hemodialysis : Relationships with patient and vascular access survival. Am J Kidney Dis 1993; 22: 215–225
   PubMed Web of Science ®Google Scholar
• Okura Y, Saku K, Hirata K, Zhang B, Liu R, Ogahara S, Naito S, Kajiyama G, Arakawa K. Serum lipoprotein (a) levels in maintenance hemodialysis patients. Nephron 1993; 65: 46–50
   PubMed Web of Science ®Google Scholar
• Scanu A M, Lawn R M, Berg K. Lipoprotein (a) and atherosclerosis. Ann Int Med 1991; 115: 209–218
   PubMed Web of Science ®Google Scholar
• Scanu A M. Genetic basis and pathophysiological implications of high plasma Lp(a) levels. J Intern Med 1992; 231: 679–683
   PubMedGoogle Scholar
• Boerwinkle E. Genetics of plasma lipoprotein (a) concentrations. Curr Opin Lipidol 1992; 3: 128–136
   Google Scholar
• Murai A T, Miyahara N, Fujimoto M, Matusda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986; 62: 249–257
   PubMedGoogle Scholar
• Hoefler G, Harnoncourt F, Paschke E, Mirth W, Pfeiffer K H, Kostner G M. Lipoprotein Lp(a). A risk factor for myocardial infarction. Arteriosclerosis 1988; 8: 398–401
   PubMedGoogle Scholar
• Rhoads G G, Dahlen G, Berg K, Morton N E, Dannenberg A L. Lp(a) lipoprotein as a risk factor for myocardial infarction. J Am Med Assoc 1986; 256: 2540–2544
   PubMed Web of Science ®Google Scholar
• Hearn J A, Donohue B C, Ba'albaki H, Douglas J S, King S B, III, Lembo N J, Roubin G S, Sgoutas D S. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992; 69: 736–739
   PubMed Web of Science ®Google Scholar
• Hoff H F, Beck G J, Skibinski C I, Jurgens G, O'Neill J, Kramer J, Lytle B. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 1988; 77: 1238–1244
   PubMedGoogle Scholar
• Friedewald W T, Levy R I, Fredrickson D S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 409–502
   Google Scholar
• Silberman S R, Armentrout M A, Vella F A, Saha A L. MACRA (TM) Lp(a) for quantitation of human lipoprotein (a) by enzyme linked immunoassay (abstract). Clin Chem 1990; 36: 961
   Google Scholar
• Senti M, Romero R, Pedro-Botet J, Pelegri A, Nogués X, Rubiés-Prat J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992; 41: 1394–1399
   PubMed Web of Science ®Google Scholar
• Stampfer M J, Sacks F M, Salvini S, Willett W C, Hennekens C H. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. N Engl J Med 1991; 325: 373–381
   PubMed Web of Science ®Google Scholar
• Keys A. Seven Countries. A Multivariate Analysis of Death and Coronary Heart Disease. Harvard University Press, Cambridge, MA 1980
   Google Scholar
• Rader D J, Brewer B, Jr. Lipoprotein (a). Clinical approach to a unique atherogenic lipoprotein. J Am Med Assoc 1992; 267(8)1109–1112
   Google Scholar
• Boerwinkle E, Menzel H J, Kraft H G, Utermann G. Genetics of the quantitative Lp(a) lipoprotein trait. Hum Genet 1989; 82: 73–78
   PubMed Web of Science ®Google Scholar
• Traindl O, Reading S, Franz M, Watschinger B, Klauser R, Pidlich H, Widhalm K, Pohanka E, Kovarik J. Treatment of hyperlipidemic kidney graft recipients with lovastatin: Effect on LDL cholesterol and lipoprotein (a). Nephron 1992; 62: 394–398
   PubMedGoogle Scholar
• Bimmermann A, Boerschmann C, Schwartzkopff W, von Baeyer H, Schleicher J. Effective therapeutic measures for reducing lipoprotein (a) in patients with dyslipidemia. Lipoprotein(a) reduction with sustained release bezafibrate. Curr Ther Res 1991; 49: 635–643
   Google Scholar
• Kapelrud H, Bangstad H-J, Dahl-Jorgensen K, Berg K, Hanssen K F. Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria. Br Med J 1991; 303: 675–678
   PubMed Web of Science ®Google Scholar
• Hearn H A, DeMaio S J, Jr, Roubin G S, Hammarstrom M, Sgoutas D. Predictive value of lipoprotein (a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. Am J Cardiol 1990; 66: 1176–1180
   PubMedGoogle Scholar
• Ramirez L C, Arauz-Pachero C, Lackner C, Albright G, Adams B V, Raskin P. Lipoprotein (a) levels in diabetes mellitus. Relationship to metabolic control. Ann Intern Med 1992; 112: 42–47
   Google Scholar
• Haffner S M, Tuttle K R, Rainwater D L. Decrease of lipoprotein (a) with improved metabolic control in subjects with insulin-dependent diabetes mellitus. Diabetes Care 1991; 14: 302–307
   PubMedGoogle Scholar
• Levitsky L L, Scanu A M, Gould S H. Lipoprotein (a) levels in Black and White children and adolescents with IDDM. Diabetes Care 1991; 14: 283–287
   PubMedGoogle Scholar
• Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992; 89: 1166–1171
   PubMed Web of Science ®Google Scholar
• Rosseneu M, Labeur C, Vinaimont N, De Slypere J R, Matthys S E. Plasma Lp(a) patterns after triglyceride infusion. Atherosclerosis Rev 1991; 22: 137–143
   Google Scholar
• Valimaki M, Laitinen K, Ylikahrit R, Ehnholm C, Jauhiainen M, Bard J M, Fruchart J C, Taskinen M R. The effect of moderate alcohol intake on serum apolipoprotein A-1 containing lipoproteins and lipoprotein (a). Metabolism 1991; 40: 168–172
   Google Scholar
• Thomas M E, Freestone A, Varghese Z, Persaud J W, Moorhead J F. Lipoprotein (a) in patients with proteinuria. Nephrol Dial Transplant 1992; 7: 597–601
   PubMed Web of Science ®Google Scholar
• Webb A T, Plant M, Reaveley D A, O'Donnell M, Luck V A, O'Connor B, Seed M, Brown E A. Lipid and lipoprotein (a) concentrations in renal transplant patients. Nephrol Dial Transplant 1992; 7: 636–641
   PubMedGoogle Scholar
• Murphy B G, McNamee R, Duly E, Henry W, Archbold P, Trinick T. Increased serum apolipoprotein (a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis. Atherosclerosis 1992; 93: 53–57
   PubMedGoogle Scholar
• Thillet J, Faucher C, Belkacem I, Allouache M, Chapman J, Jacobs C. Lipoprotein (a) in patients treated by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993; 22: 226–232
   PubMedGoogle Scholar
• Wanner C, Rader D, Bartens W, Krämer J, Brewer H B, Schollmeyer P, Wieland H. Elevated plasma lipoprotein (a) in patients with the nephrotic syndrome. Ann Intern Med 1993; 119: 263–269
   PubMedGoogle Scholar
• Kraft H G, Menzel H J, Hoppichler F, Vagel W, Uterman G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989; 83: 137–142
   PubMed Web of Science ®Google Scholar
• Krempler F, Kostner C M, Bolzano K, Sandhofer F. Turnover of lipoprotein (a) in man. J Clin Invest 1980; 65: 1483–1490
   PubMed Web of Science ®Google Scholar
• Krempler F, Kostner G M, Roscher A, Haslauer F, Bolzano K J. Studies on role of specific cells surface receptors in the removal of lipoprotein (a) in man. J Clin Invest 1983; 71: 1431–1441
   PubMed Web of Science ®Google Scholar
• Karadl I, Romics L, Palos G, Doman J, Kaszas I, Hegz A, Kostner G M. Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989; 35: 2121–2123
   PubMedGoogle Scholar
• Dulaney J T, Hatch F E, Jr. Peritoneal dialysis and loss of protein : a review. Kidney Int 1984; 26: 253–262
   PubMed Web of Science ®Google Scholar
• Bewu A D, Durrington P N. Lipoprotein (a): Structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990; 85: 1–14
   PubMedGoogle Scholar
• Bersot T P, Innerarity T L, Pitas R E, Rall S C, Weisgraber K H, Mahley R W. Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein (a) and that cause lipid accumulation in macrophages. J Clin Invest 1986; 77: 622–630
   PubMedGoogle Scholar
• Adrogué H J. Glucose homeostasis and the kidney. Kidney Int 1992; 42: 1266–1282
   PubMedGoogle Scholar
• Hofmann S L, Eaton D L, Brown M S, McConathy W J, Goldstein J L, Hammer R E. Overexpression of human low density lipoprotein receptors lead to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest 1990; 85: 1542–1547
   PubMed Web of Science ®Google Scholar
• Kostner G M. The physiological role of Lp(a). In Lipoprotein (a), A M Scann. Academic Press, San Diego 1990; 183–204
   Google Scholar
• Loscalzo J. Lipoprotein (a): A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990; 10: 672–679
   PubMedGoogle Scholar